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Abstract: The purpose of this review is to examine the latest literature on the use of autologous
platelet-rich fibrin as a drug and growth factor carrier system in maxillofacial surgery. Autologous
platelet-rich fibrin (PRF) is a unique system that combines properties such as biocompatibility
and biodegradability, in addition to containing growth factors and peptides that provide tissue
regeneration. This opens up new horizons for the use of all beneficial ingredients in the blood
sample for biomedical purposes. By itself, PRF has an unstable effect on osteogenesis: therefore,
advanced approaches, including the combination of PRF with materials or drugs, are of great interest
in clinics. The main advantage of drug delivery systems is that by controlling drug release, high drug
concentrations locally and fewer side effects within other tissue can be achieved. This is especially
important in tissues with limited blood supply, such as bone tissue compared to soft tissue. The ability
of PRF to degrade naturally is considered an advantage for its use as a “warehouse” of controlled
drug release systems. We are focusing on this concentrate, as it is easy to use in manipulations and
can be delivered directly to the surgical site. The target audience for this review are researchers
and medical doctors who are involved in the development and research of PRFs further studies.
Likewise, surgeons who use PRF in their work to treat patients and who advice patients to take the
medicine orally.
Keywords: platelet-rich fibrin; endogenous growth factors; carrier systems; drug delivery; platelet
concentrates; tissue engineering; autologous growth factors
1. Introduction
Although many approaches to bone tissue engineering have traditionally focused on
synthetic materials (such as polymers or hydrogels), nowadays new emerging methods
involve the use of natural materials due to their biological properties, such as autologous
bone grafting. It is still debated whether platelets can be considered as cell fragments
or whole cells [1], but they are known to be responsible for the activation and release of
biomolecules. The growth factors that accelerate the wound healing process. Due to this,
the use of platelet concentrates has been known for more than four decades [2]. Platelet-rich
fibrin (PRF) is an autologous material that is easily produced; it can be derived from a
person’s own blood and is used to promote wound healing and tissue regeneration. PRF
can be used in various fields of medicine, including dentistry and maxillofacial surgery [3].
PRF is expected to have a direct effect on enhancing tissue regeneration by saturating these
tissues with growth factors from the blood. The autologous nature of PRF makes it the
preferred choice for a variety of biomaterials in use today.
In this review, we considered 4 types of platelet concentrates as a possible drug
delivery systems listed in Table 1.
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Table 1. Abbreviation of different platelet concentrates.
Abbreviation Platelet Concentrate Explanation
PRP Platelet-rich plasma First-generation platelet concentrate withhigh platelet concentrations [4]
PRF Platelet-rich fibrin Second-generation platelet concentrate [5]
i-PRF Injectable platelet-rich fibrin
Advanced version of PRF in liquid
form which can be injected and contains stem
cells with high regenerative potential [6]
A-PRF Advanced platelet-rich fibrin An autogenous blood product withapplications in dento-alveolar surgery [7]
Several studies have reported that these platelet concentrates are most commonly used
in medicine. There are also articles on other platelet concentrates, such as pure platelet-rich
plasma (P-PRP), leukocyte-platelet-rich plasma (L-PRP), pure platelet-rich fibrin (P-PRF),
and leukocyte- and platelet-rich fibrin (L-PRF). These concentrates are used alone or in
combination with bone grafts. To promote tissue regeneration the platelet concentrates
should contain not only platelets, but also substances in our blood, such as growth factors
and host immune cells. Various growth factors are known to promote wound healing, with
PRF being able to release them slowly. In addition, when combined with drugs, they can
provide faster recovery and reduce the risk of infections. Platelet-rich plasma contains
large amounts of platelets and is injectable, while not as easy to prepare and use it [8].
The second type of platelets, platelet-rich fibrin (PRF), plays an important role in
modern medicine and is used as one of the components in the production of biomaterials.
As mentioned in several sources, PRF is a second-generation platelet concentrate derived
from centrifuged blood [5] and, in addition to platelets, also contains white blood cells,
serum and concentrated growth factors [9], such as platelet-derived growth factor (PDGF),
transforming growth factor-β (TGF-β) and insulin-like growth factor 1 (IGF-I) [10]. The
properties of growth factors and cytokines within the PRF are shown in Table 2.
Table 2. Description of growth factors and cytokines within the PRF.
Abbreviation Growth Factor/Cytokine Properties
PDGF Platelet-derived growth factor
Provides fibroblast chemotaxis [11], extracellular matrix modification
[12], and increases TGF-β release from macrophages [13]. Its addition
ensures the growth of cultured cells [14] and improves bone cell
proliferation [15]
TGF-β Transforming growth factor β
A multifunctional cytokine [16] and one of 30 members of the
superfamily [5] that has been shown to promote extracellular matrix
formation [15]. The most common of the three isoforms [13] of TGF-β
is TGF-β1, which has the ability to stimulate the production of collagen
and fibronectin in cells [17]
IGF-I Insulin-like growth factor I
A growth hormone-dependent polypeptide that stimulates skeletal
growth in vivo [18], has an effect on the behavior of cells, thus
providing tissue regeneration [19]
VEGF Vascular endothelial growthfactor
Promotes the proliferation [20] of endothelial cells and stimulates their
migration [21]. It plays an important role in the cardiovascular system,
increasing blood flow and enriching the injury site with nutrients [22].
In addition, it plays a role in bone formation and wound healing [23]
IL-1β Interleukin-1β Plays an important role in protection against infections and injuries[24], it is also involved in the activation of monocytes [25]
Int. J. Mol. Sci. 2021, 22, 11553 3 of 18
Table 2. Cont.
Abbreviation Growth Factor/Cytokine Properties
IL-6 Interleukin-6
Able to respond to infections and tissue injuries by stimulating
hematopoiesis [26]. The main signal enhancement pathway [20] upon
exposure to epithelium and immune cells [27]
IL-4 Interleukin-4
Acts as a powerful immune regulator [28] that inhibits the proliferation
of osteoblast-like cells in vitro [29] and modulates the regeneration of
macrophage cells [30]. It is also able to stimulate the accumulation of
extracellular matrix macromolecules [31]
TNF-α Tumor necrosis factor-α
Provides growth and differentiation of different cell types [32].
Stimulates the ability of fibroblasts to transform [20], and regulates the
activity of vascular endothelial cells and keratinocytes. Determines the
synthesis of extracellular matrix proteins [33]; it plays a key role in
healing inflammation and wounds [34]
PRF is widely used to accelerate soft and hard tissue regeneration [17]. This was first
described by Choukroun and his group in 2001 in France [35]. The PRF production protocol
originally developed by his group used 10 mL of anticoagulant-free blood sample that was
centrifugated at 2700 rpm for 12 min [16]. PRF is a modification of platelet rich plasma
(PRP) and at the same time an autologous fibrin matrix used to improve bone regener-
ation and clinically used for soft tissue augmentation [10]. Compared to other platelet
concentrates, PRF is a platelet-rich fibrin clot that does not require the use of thrombin
(anticoagulants which used to accelerate gelation), but only centrifuged blood without any
impurities [36,37]. It is a new biomaterial that resembles an autologous cicatrical matrix,
but at the same time is neither a fibrin glue or a classic platelet concentrate [38]. The absence
of anticoagulants does not delay the cascade of wound healing allowing natural blood clots
to form. In addition, PRF contains a high concentration of host immune cells, which are
needed to heal wounds and reduce infections [39].
Compared to platelet-rich plasma (PRP) (it requires multi-stage centrifugation in
combination with the addition of non-autologous anticoagulants and the additional use
of bovine thrombin or calcium chloride [16]), PRF does not dissolve for following hours
after application, on the contrary it is slowly destroyed in the same way as a natural
blood clot [40]. As mentioned above, bovine thrombin or anticoagulant is not required
to obtain PRF, thus PRF provides lower costs and fewer disadvantages of biochemical
modifications [8]. After centrifugation, PRF still combines many of the healing and immune
enhancers found in the initial blood [17]. After injection, unlike PRP, liquid PRF (i-PRF)
is rapidly converted to fibrin and, similarly to PRP, i-PRF is used for the local delivery of
autologous angiogenic and regenerative growth factors [2,41].
Different platelet-rich fibrin (PRF) derivatives are used today depending on the appli-
cation and the desired properties. Efficacy of autologous platelet concentrates in promoting
wound healing and tissue regeneration is at the center of a recent academic debate [42]. In
this review, we will consider few of the PRFs mentioned above that have attracted the most
attention as drug delivery systems, and will try to understand which type of PRF is better
and more suitable for development of controlled drug delivery systems.
2. Materials and Methods
Articles were searched for keywords such as “platelet-rich fibrin”, “growth factors
PRF”, “drug delivery systems PRF”, “platelet-rich fibrin”, “antibiotics PRF”, “drug PRF”,
and “drug fibrin”. In case it was necessary to find other articles with the PRF that included
the specified drug, then the name of the drug was used as a keyword. Emphasis on the
literature related to PRF clinical trials and studies investigating drug incorporation, growth
factor secretion was placed. Antibacterial studies to understand whether drugs can provide
antibacterial efficacy by being included in the PRF matrices were also reviewed in relation
to drug studies. Databases such as PubMed/MEDLINE, ScienceDirect, Scopus were used
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for search. In total, 200 studies were found for the above keywords, from which 121 articles
were selected for further analysis in this review.
3. From Blood to Injectable or Solid System
i-PRF is liquid injectable PRF and allows the incorporation of drugs and drug delivery
systems prior to coagulation. i-PRF is a recently introduced platelet concentrate [43] that
can be easily combined with various biomaterials [44] to improve the properties of the
biomaterial. i-PRF contains not only autologous growth factors found in the blood, but also
cells involved in the wound healing process [45] (Figure 1). The functions of cells found in




Figure 1. Main elements of blood (A) and PRF (B). Panel B shows that not all elements in the blood
enter the PRF layer after centrifugation. Both figures created with Biorender.com.
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Table 3. Description of cells within the PRF.
Cell Type Functions
Platelets Involved in primary wound closure and able to release several growthfactors to attract inflammatory cells to the site of injury [46,47]
Leukocytes Essential for tissue regeneration as they direct and attract different typesof cells in the wound healing process [44]
Red blood cells
Physical and chemical interactions between platelets and the blood
surface may be provided [48]. Induces an increase in platelet
concentrations at the site of action and in vitro coordination [49]
Neutrophils Play an important role in healing processes [50]. Serves as the firstsignals for the activation of local fibroblasts and keratinocytes [51]
Lymphocytes It affects the osteogenic differentiation of mesenchymal stromal cells [52]and releases a wide range of cytokines [53]
Monocytes A key role in supporting tissue homeostasis by disseminating immuneresponses to convenience [54]
Stem cells
Play an important role in regenerative medicines [55], also have the
opportunity to regenerate and differentiate in different types of cells [56].
PRF is a unique source of hematopoietic stem cells (HSCs) [57]
After about 20 min fibrin is polymerized (the liquid state of PRF depends on the
speed, G-force and time of centrifugation), during which fibrin changes from a liquid state
to a solid, forming a three-dimensional fibrin network. This network contains cellular
components that are distributed in the network and ensure the slow and steady release of
growth factors over a period of time. In addition, a controlled release system maintains
bioactivity throughout healing [4]. As mentioned by Bennardo et. al., liquid PRF can also
be used as an injection to treat lichens [58].
A-PRF, on the other hand, is a solid system (in the form of a clot) that can be com-
pressed and used as a strong membrane. Modification of PRF preparation procedures
at lower centrifugation rates with lower G-forces results in A-PRF with higher levels of
growth factors [9]. This is indicated by a Caruana et.al group study on the variability
of TGF-β1 and VEGF growth factor concentrations depending on the change in the PRF
preparation protocol. At high relative centrifugal force (RCF), they obtained PRF with
TGF-β1 less than 2000 pg/mL and VEGF equal to 0 pg/mL. The use of a moderate RCF
protocol increases the concentration of growth factors, resulting in TGF-β1 greater than
2000 pg/mL and VEGF greater than 10 pg/mL. On the other hand, when RCF was reduced
to low, a 2-fold increase in growth factors was observed, resulting in TGF-β1 > 4000 pg/mL
and VEGF > 20 pg/mL [59]. Due to the high concentration of growth factors, A-PRF has
the potential to mimic the physiology and immunology of wound healing [60]. During the
production of A-PRF, it is important to maintain platelets, leukocytes, circulating stem cells
and endothelial cells in the fibrin clot [9]. In the A-PRF obtained by the Choukroun et al.
group method, the white blood cell count includes more neutrophils, which ensures tissue
regeneration and vessel formation [61] due to its ability to promote the anti-inflammatory
state of macrophages [60]. As mentioned by Wend et al., in addition to solid PRF, there is
a clinical need to develop injectable PRF matrices for various clinical procedures and to
improve angiogenic potential through the ability to combine i-PRF with various biomateri-
als [52]. Figure 2 shows the advantages of i-PRF and A-PRF. The idea of the review is to
show that these 2 types of PRFs can be used as candidates for the development of drug
delivery systems. That they are the ones that contain more growth factors that can ensure
wound healing.













Figure 2. Comparison of the advantages for two concentrates i-PRF and A-PRF. Figure created with Biorender.com. 
4. Therapeutic Enhancement of PRF 
The most common postoperative risk of minor surgeries is infection caused by mem-
brane exposure and colonization of wound bacteria [62,63]. PRF itself may show antibac-
terial activity, but it has not been relatively well studied and there are insufficient data on 
what affects it. The main unanswered questions are: 1. Does it depend on the concentra-
tion or on the characteristics of the patient’s blood? 2. If derived from a patient, then what 
properties are crucial to obtain a PRF antibacterial? There are also no data against which 
bacteria PRF itself may be antibacterial and which certain antibiotics must be added. In 
an attempt to delve into this issue, studies were found describing the antibacterial activity 
of L-PRF (leukocyte- and platelet-rich fibrin) [64,65] and H-PRF (PRF prepared by hori-
zontal centrifugation) samples [65]. Another study looked at the antimicrobial properties 
of i-PRF against biofilm formation produced by certain Staphylococcal isolates, indicating 
the need to further investigate the antimicrobial properties of i-PRF based on an in vivo 
model [66]. This is also confirmed by other studies indicating that PRF has only mild an-
tibacterial activity against some bacterial agents, including S. aureus, and does not show 
efficacy against resistant bacteria [67,68]. In turn, it is known that there are other bacterial 
isolates against which i-PRF would need to be antibacterial. 
Oral administration of drugs is sometimes ineffective because absorption is irregular 
and incomplete in the most cases. Changes in drug solubility can occur as a result of reac-
tion with other materials in the gastrointestinal tract. It is not suitable for emergencies 
where the medication must be taken as soon as possible, since the onset of action of the 
oral medication is relatively slow (long process from intake to destination) [69]. In addi-
tion, a significant advantage of local drug delivery is the ability to achieve high and stable 
Figure 2. Comparison of the advantages for two concentrates i-PRF and A-PRF. Figure created with Biorender.com.
4. Therapeutic Enhancement of PRF
The most common postoperative risk of minor surgeries is infection caused by mem-
brane exposure and colonization of wound bacteria [62,63]. PRF itself may show antibacte-
rial activity, but it has not been relatively well studied and there are insufficient data on
what affects it. The main unanswered questions are: 1. Does it depend on the concentration
or on the characteristics of the patient’s blood? 2. If derived from a patient, then what
properties are crucial to obtain a PRF antibacterial? There are also no data against which
bacteria PRF itself may be antibacterial and which certain antibiotics must be added. In an
attempt to delve into this issue, studies were found describing the antibacterial activity of
L-PRF (leukocyte- and platelet-rich fibrin) [64,65] and H-PRF (PRF prepared by horizontal
centrifugation) samples [65]. Another study look d at the antimicrobial properti s of i-PRF
against biofilm formation produced by certai Staphylococcal isolates, indicating the need
to fur her i vesti e the ntimicrobial pr perties of i-PRF based on an in vivo model [66].
This is also confirmed by other studies indicating that PRF has nly mild antibacterial
activity against some bacteri l agents, including S. aureus, and does not sh w efficacy
against resistant bacteria [67,68]. In turn, it is known that there are other bacterial isolates
against which i-PRF would need to be antib ct rial.
Oral dministration of drugs is sometimes ineffective because absorption is i regular
and incomplete in the most cases. Changes in drug solubility can occur as a result of
reaction with other m erials in the gastroin estinal tract. It is not suit le for emergencies
where the edication must be t k n as soon as possible, since the o set of action of the o al
medication is relatively slow (long process from intake to destination) [69]. In addition, a
significant advantage of local drug delivery is the ability to achieve high and stable l cal
drug concentrations without high systemic doses, thereby reducing systemic toxicity [70].
Based on the collected literature on the antibacterial properties of PRF, we believe that it
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would be ideal to combine it with drugs to form a single system, rather than using separate
drugs and PRF. In the last decade, there are few studies that combine antibiotics with PRF
to provide an antibacterial effect.
The literature has reported that PRF is often combined with drugs, such as metron-
idazole, clindamycin, penicillin [71], vancomycin, teicoplanin, gentamicin, or amikacin
to kill bacteria and speed up the healing process [72]. Today, in oral and maxillofacial
surgery (including the prevention and treatment of osteonecrosis of the jaw [73]), there is
an increasing demand for clindamycin as a drug. It is widely regarded as an alternative for
patients who have an allergic reaction to penicillin [74]. Below we have shown the possible
applications of PRF with drugs, the studies are systematized by drug classes.
The studies related to the combination of PRF with the drugs are shown in the Table 4.
Table 4. Various drugs for inclusion in platelet-rich fibrin system (summary of the drugs in platelet-rich fibrin system).
Drug Incorporation Method Time of the Study Reference
Clindamycin Drug mixing in a bloodsample, use of PRF clot 4 days [71]
Lincomycin Drug mixing in a bloodsample, use of PRF clot 10 days antibacterial activity [75,76]
Amikacin, teicoplanin or
polyhexanide
PRF mixing with drug, using
co-delivery applicator
168 h for amikacin, 120 h for




1% Alendronate gel PRF combinated with drugs 9 months [77,78]
1.2% Atorvastatin
Drug combination with PRF
and open flap debridement
(OFD)
9 months [79]
1.2% Rosuvastatin gel Drug gel adding into PRFmembrane 9 months [80]
1% Metformin Drug combination with PRFand OFD 9 months [81–83]
Diclofenac sodium Drugs injected in PRF usingneedle 7 days [84]
Triple antibiotic mixture (MET
+ CIP + MINO)
Antibiotic mixture mixing









Amoxicillin Drugs used orally 1 h beforeblood collection 48 h [64]
4.1. Antibiotics
Antibiotics are considered to be an effective treatment for various types of infections
caused by bacteria (gram-positive and gram-negative). In turn, their misuse can lead to
antibiotic resistance [87]. Wound healing is a normal biological process in the human
body, but in the postoperative period there is a high risk that there may be factors that will
affect this process. It is important to ensure a proper healing process and reduce the risk
of infections [88]. For wound healing, PRF can also be used as a drug carrier in another
system. Therefore, we collected the literature in which PRF is used in combination with
antibiotics to determine if PRF can provide antibiotic therapy at wound sites. One of the
discovered studies described a method in which PRF together with one of 3 different drugs
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(amikacin, teicoplanin, and polyhexanide (a group of drugs used to treat wounds)) was
sprayed onto a patch and tested for antimicrobial activity for 7 days. The results showed
that for amikacin antimicrobial activity was observed up to 120 h, for teicoplanin —168 h,
while for polyhexanide it can be observed only for 24 h [72]. This study indicates that
it is possible to obtain a system in which certain drugs are dispensed at a specific time,
providing the necessary therapy.
Lincosamides
This class of drugs is obtained from Streptomyces spp. [89]. Lincosamides are mainly
used to treat anaerobic infections caused by gram-positive organisms, including infections
developed by methicillin resistant Staphylococcus aureus [90]. Originally this class of antibi-
otics comes from natural product lincomycin, but derivatives also include clindamycin
and pirlimycin, from which clindamycin is the most clinically relevant lincosamide [90,91].
Drugs such as lincomycin and clindamycin are bacteriostatic and inhibit protein synthesis.
In the same way, both drugs are used in clinical practice and at higher concentrations
in in vivo, they will become bactericide [92]. Clindamycin has been shown to be more
effective than lincomycin in treating bacterial infections. In turn, doctors choose it for the
treatment of odontogenic infections. The choice of doctors can be explained by the fact that
clindamycin has not only bactericidal activity, but also significant tissue distribution and
low resistance [93].
Summarizing the literature on current in vitro studies, it was found that there was
one study in which lincosamide, a clindamycin, was included in the A-PRF. There is direct
mixing of the drug in the blood sample and afterwards A-PRF clot was used. This system
is relatively easy to obtain and can provide drug release for up to 4 days. However, in
order to be used for further studies, it would have to be processed if a non-cylindrical
sample was required. Additionally, this sample is not injectable, so it can be used as a
ready-made clot, without the possibility to use to fill the defect site. In addition, this
study lacks data on the effectiveness of drug encapsulation, which cannot predict what
percentage of added drugs are encapsulated [71]. The effect of lincomycin form and volume
on the antibacterial activity of PRF after 24 h, 48 h, 120 h, and 240 h was also studied using
the drug in 3 forms (ampoule, capsule-mixed with saline and powder). The results showed
that greater antibacterial activity was obtained by adding ampoule-type lincomycin to a
blood sample [75,76].
4.2. Bisphosphonates
It is a group of medicines that are used in osteoporosis (a systemic skeletal disease
that results in increased bone fragility and susceptibility to fractures [94]) and when the
bone is not formed properly [95]. The most common condition that causes bone defects
is periodontitis (an inflammatory disease of the supporting tissues of the teeth caused
by certain microorganisms or groups of certain microorganisms [96]). It is believed that
intrabony defects are less prevalent than horizontal bone loss. Intrabony defects pose
a risk of disease progression and need to be treated. Looking at the literature, one gets
the impression that not all intrabony defects can be cured. Due to the development of
new biomaterials by scientists, it is likely that dental prognosis will be improved [97].
An interesting fact is that the combination of PRF with drugs can be used to treat this
disease. Some studies [77,78] have described that PRF is used in combination with drugs,
such as alendronate (ALN) to treat this disease. In the first study, combining 1% ALN gel
with A-PRF, the researchers tried to prove the effectiveness of a combination of the two
in treating grade II mandibular furcation defects compared to PRF. The PRF/1% ALN gel
composition allowed to fill a higher percentage of defects (56.01 ± 2.64%), where simply for
PRF therapy (49.43 ± 3.70%), indicating that the PRF/1% ALN combination has a recovery
potential [77]. In the second study, the PRF/1% ALN combination is already being studied
for the treatment of intrabony defect in chronic periodontitis. As in the previous study,
the PRF/1% ALN combination was able to provide a greater reduction in defect depth
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(54.05 ± 2.88%) compared to PRF (46 ± 1.89%) [78]. As can be seen, both studies have
similar results, confirming the reliability of the results of the PRF/1% ALN combination.
This study indicates that the use of PRF in combination with a bisphosphonate drug can be
used to reduce the size of the defect.
4.3. Statins
It is a class of drugs that is effectively used to lower cholesterol and also to reduce
the risk of cardiovascular morbidity and mortality [98]. At the time of writing this report,
studies were found where a representative of this class of drugs is used in the treatment of
intrabony defects. Martande et al. in their study used 1.2% atorvastatin gel in combination
with A-PRF and open flap debridement (OFD) to achieve the desired outcome [79]. Scien-
tists have concluded that additional studies related to the use of PRF in the treatment of
intrabony defects may reduce the number of patients with periodontitis. Another study
also looked at the effect of the combination of the drugs and the PRF on clinical parameters.
In this study alone, rosuvastatin (RSV) was selected as a drug, and the effects of open-flap
debridement (OFD) with or without PRF and PRF/RSV were further investigated. In the
present study, Pradeep at. al study results showed that combining RSV with PRF provided
greater periodontal benefits compared to OFD alone or OFD/PRF [80]. The results of this
study are similar to those of Pradeep et al. studies where RSV gel was used in combination
with PRF and hydroxyapatite bone graft [99]. Both of the above studies indicate that statin
drugs can be used not only for the treatment of blood and vascular diseases, but also for
the treatment of other, no less common diseases, thus expanding the use of the drug.
4.4. Biguanides
Biguanides are a class of herbal drugs [100] classified as non-sulfonylureas that act
directly against insulin resistance [101]. In addition to one of the drugs in the class of statins,
biguanide drugs can be used to treat intrabony defects. As one of these drugs, Pradeep
et al. used 1% metformin (MTF) in combination with A-PRF and OFD in their study [83].
As with statins, metformin has been shown to reduce periodontitis. A similar study was
performed Taneja et.al, comparing the differences between PRF/MFT and PRF at 6 and 9
months [82]. A study was also found evaluating the possible use of OFD/PRF/MFT in the
treatment of grade II mandibular furcation defects [81]. It has been shown that biguanide
drugs in combination with PRF is widely used in periodontal therapy, which indicates the
ability of PRF to be a drug delivery vehicle.
4.5. Non-Steroidal Anti-Inflammatory Drugs
This class of drugs is one of the most widely used therapeutic classes in clinical
medicine [102]. Additionally, drugs in PRF can be incorporated not only by mixing in
the blood or by mixing with i-PRF, they can be injected with a needle into the A-PRF
clot obtained after centrifugation. This method was used by Pillai et al. in their study to
administer diclofenac to test whether the PRF as a carrier would be able to deliver the drugs
locally. Their study was more based on comparing pure PRF with PRF/diclofenac on the
basis of clinical parameters (postoperative pain, swelling, soft tissue healing, and infection
risk, etc.). The obtained results confirmed the hypothesis that PRF/diclofenac gel improves
the clinical parameters, thus indicating that such a method of drug administration can
improve the wound healing process and promote bone regeneration [84].
4.6. PRF Combination with Several Drugs
Another interesting fact is that PRF can combine not only one type of drugs, but also a
mixture of several drugs. In the study where i-PRF was mixed with the triple drug mixture
(metronidazole (MET), ciprofloxacin (CIP), minocycline (MINO)), release was observed
for up to 28 days, but burst release was already observed within the first 24 h [85]. If a
high concentration one of these drugs is included in the i-PRF with a view to prolonged
therapy, it is likely that a toxic drug concentration will be released within the first 24 h and
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the required controlled drug therapy will not be achieved. The study also says that the
simultaneous release of all three drugs takes only 14 days, followed by the release of only
MINO and MET, resulting in the loss of i-PRF from its initial use.
4.7. PRF Combination with Materials and Drugs
Another way to restore diseased or damaged bones is bone grafting. Nowadays, it
receives a lot of attention today due to the slow and difficult integration of the grafted
material. Platelet concentrates are used to improve this integration process, which also
accelerates bone and mucosal healing. PRF is no exception, which, regardless of the way
it is used (membranes or fragments), can be used to protect a surgical site after surgery.
To protect the bone graft from anaerobic bacterial infections, the Simonpieri team added
metronidazole to the PRF membrane combinated with freeze-dried bone allograft. In
addition, the combination of these two excipients improved the histological quality of bone
tissue in the graft [86].
In most cases, the drugs are mixed into the PRF, creating the necessary material to
treat a specific problem. In contrast, there is a study in which the drug is first taken
orally, indicating that administration of the drug to a previously acquired PRF system
is not the only way to improve antibacterial efficacy. This time, an attempt was made
to determine whether L-PRF, prepared after a single dose of oral antibiotic, was able to
produce significant antimicrobial activity within 48 h. After 48 h, no sterile area was
observed, indicating that 1 dose of oral antibiotic was insufficient to provide 48 h of
antimicrobial activity. The data suggest that most antibiotics are concentrated in plasma
and that only a small proportion of them end up in the PRF [64]. The drug concentration
in the PRF after an oral drug consumption should be determined. The calculated amount
could be used as ground for further use of the drugs. Additionally, it has to be investigated,
is the calculated amount of the drug is safe to use in medical practice.
Looking at all of the studies described above, there is a tendency to combine PRF with
drugs. However, several of these studies show insufficient analysis and lack of data (drug
release time and amount).
5. PRF as a Bioactive Agent in Different Matrices
One of the main requirements for carrier systems is the controlled release of the
drugs and growth factors they contain (the bioactive molecule is delivered locally or
systemically at a specific rate over a period of time). There are studies describing the
successful combination of cells and growth factors or biomolecules with non-autologous
fibrin. In turn, the autologous liquid i-PRF offers additional advantages as a carrier system
for cells and growth factors [45] (Figure 3).
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In this section, we have summarized the studies in which the PRF serves as a carrier
system of bioactive molecules or was included in one of the carrier systems (Table 5).
Table 5. Carrier systems incorporated in injectable platelet-rich fibrin.
Carrier System Target Incorporation Method Time of the Study Reference
G-L-PRF Accelerate wound healing
Fresh lyophilized PRF added
to PVA hydrogels (simple
physical method)
9 days [103]
PRF granules Improve periodontalhealing
PDLSC cultivated with PRF
membrane 7 days [104]





Adding PRF into DBC/fibrin
glue 36 weeks [106]
Gelatin nanoparti Get mechanically toughand bioactive hydrogel
Mixing i-P it NPs by
repetitive extrusion 3 weeks [107]
Collagen membrane
Enhance th tivity of
collagen-based
biomaterials
Liquid-PRF is applied to
collagen membrane 24 h [108]
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Table 5. Cont.
Carrier System Target Incorporation Method Time of the Study Reference
PRF Prevent peri-implant defect Silk fibroin mixing with PRFin vivo 8 weeks [109]
PRF membrane Treatment of furcationdefect
β-TCP granules insertion at
the defect site and sealing with
a PRF membrane
9 months [110]
PRF membrane Treatment of intrabonydefects ABBM mixed with PRF 6 months [111]
PRF membrane Treatment for periodontalintrabony defects BPBM mixed with PRF 6 months [112]
PRF could not only serve as a carrier, but also be placed in another material. Xu
et al. group described a study in which fresh granule-lyophilized platelet-rich fibrin
(G-L-PRF) was incorporated into polyvinyl alcohol (PVA) hydrogels to improve wound
healing. The results showed that increasing the G-L-PRF concentration could improve
the mechanical strength and degradation rate of the scaffolds, but the concentration did
not affect the flexibility and biocompatibility of the scaffolds. Regarding growth factors,
the incorporation of G-L-PRF into PVA hydrogels provided a sustained and controlled
release of growth factors from G-L-PRF/PVA scaffolds for up to 9 days [103]. Summarizing
the literature, it was found that using PRF it is possible to develop a cell transplantation
method. Such a method was developed in vitro by Zhao and his team using periodontal
ligament stem cell (PDLSC) cell sheet fragments and PRF granules. The aim of this study
was to improve periodontal healing in avulsed dental re-implantation. The results of the
study showed that PRF induces significant and continuous stimulation of proliferation in
human PDLSC throughout the 7-day incubation period, suggesting that the PDLSC/PRF
construct may improve clinical outcomes in subsequent dental re-implantations. However,
before using this method in patients, additional studies on the molecular mechanisms of
the PDLSC/PRF interaction are required to ensure reliable results [104].
Returning to wound healing, growth factors are worth mentioning as they play an
important role in the healing stages. Platelets are the main cell type in the inflammatory
phase as they release PDGF and TGF-β. Both are growth factors that attract macrophages
and neutrophils [113]. Therefore, it cannot be forgotten that PRF itself can serve as a
matrices for the growth factors that are in every person’s blood. In their study, Ehrenfest
et al. described three growth factors (TGFβ-1, PDGF-AB, VEGF) and coagulation matrix
cellular protein, thrombospondin-1, (TSP-1), and the ability to release them in large amounts
from the PRF membrane within 7 days. The results showed that comparing the amount of
growth factors initially released to the end, it can be concluded that the leukocytes in PRF
provide high TGFβ-1 and VEGF release throughout the experiment [105]. It turns out that
PRF can be combined with other related materials to improve recovery. More specifically,
this is described in a study by Yang et al., in which dental bud cells (DBC) were suspended
in fibrin glue (used as one of the most effective scaffold materials) and then A-PRF was
added. Thus, the restoration of dental tissue was achieved [106].
One of the studies is a double network (DN) hydrogel of i-PRF and gelatin nanoparti-
cles (GHPs), with the aim to obtain a mechanically strong and bioactive hydrogel that can
adapt to the irregular shape of the defect and withstand the required pressure. During this
study, the release of growth factors (VEGF, platelet derived growth factor-BB (PDGF-BB),
TGF-β and IGF-1) was observed for more than 3 weeks. This is higher compared to other
studies [44,52] where in vitro release from pure i-PRF gel occurred in 2 weeks. In addition,
DN hydrogels prevent the burst release of growth factors during the first hours [107]. The
in vivo studies, described above, have shown that PRF matrices can be perceived as carrier
systems due to their ability to release growth factors.
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It should also be mentioned that the PRF can serve not only as a drug delivery system
but also as a matrices of other materials. One ex vivo study analyzed the ability of the i-PRF
matrix to be a autologous growth factor delivery system in combination with 5 collagen-
based membranes. Thus, this was the first study that attempted to understand the ability
and suitability of biomaterials to incorporate PRF. The assay was performed by separating
leukocytes and platelets across the collagen membrane and determining the interaction
between the collagen membrane and i-PRF. The obtained results showed differences in the
structural composition of collagen membranes and differences in the interaction of collagen-
based biomaterials with liquid PRF [108]. The obtained data confirmed the previous
results that the interaction of the cell with the biomaterial is partially determined by the
structural properties of the biomaterial [114,115]. Scientists have also tried to combine
silk fibroin powder from Bombyx mori with Choukroun PRF. The results showed that the
combination of these two materials can successfully prevent peri-implant defect [109].
Regarding the inclusion of other materials in PRF, a new approach to the use of PRF
for the treatment of periodontitis defect has been explored. The approach is based on
the placement of beta-tricalcium phosphate (β-TCP) granules at the furcation defect site,
followed by the application of a PRF membrane covering both the defect site and the bone
graft. Despite the successful results, this method requires additional research to ensure its
suitability [110]. While searching for articles on the treatment of periodontitis, we found
that PRF in combination with other materials can also be used to treat intrabony defects.
In one such study, researchers combined PRF with an anorganic bovine bone (material
for transplantation into alveolar cavities after human extraction [116]) mineral (ABBM),
indicating that it is effective in treating these defects and may increase the rate of clinical
attachment [111]. A similar study was carried out by the Lekovic group, where A-PRF was
combined with bovine porous bone mineral (BPBM) instead of ABBM. Combining BPBM
with A-PRF resulted in significantly greater reductions in pocket depth, increased clinical
attachment, and defect filling than PRF used alone [112].
Summarizing all the above studies, it is observed that when using PRF as a matrices
or including it in another carrier system, there is no need to add growth factors, as PRF
itself includes certain growth factors. The only thing to consider, then, is the encapsulation
of the desired drug and its interaction with other carriers that will be included in the PRF.
It is also important to investigate whether the used carrier system will be able to ensure the
controlled release of the growth factors that are in the PRF.
6. Conclusions and Future Perspectives
Summarizing the literature on the possible application of PRF, it has been observed
that nowadays there is a growing demand for its application in operations. Several pieces
of clinical research shows that PRF can be used in different surgeries, such as open-heart
surgery, cranial surgery, endodontic surgeries, and periodontitis [117]. This allows surgeons
to use the beneficial properties of PRF to solve a given problem, such as closing a defect
and improving recovery. PRF is also widely studied as a drug delivery system to reduce
the risk of postoperative infections.
Although platelet-rich fibrin is autologous and contains growth factors and cells, its
antibacterial properties are not specifically expressed. In addition, analgesics, anticancer,
and other therapies that would otherwise be administered intravenously or orally may be
added to the PRF. For optimal drug use, it is necessary to study the effect of interaction
between PRF and drug on controlled release of the drug and the ability of the sample
to retain properties, such as biocompatibility, biodegradability, mechanical strength, and
shape retention. Already additional biomaterials are being added to the PRF to provide
these properties. However, there is a need to further explore the ability of this biomaterial
to be a drug delivery system, combining the ability of PRF to retain growth factors and
incorporate drugs.
Current research shows that most drug or drug delivery systems are mixed with the
A-PRF clot or its membrane, and the amount of growth factors or the antibacterial activity
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of the material is studied. It seems that studies of the kinetics of drug release from the
investigated samples are insufficient. Therefore, we propose to continue the study of i-PRF
as a matrix for drug delivery systems, including liquid i-PRF before coagulation, and to
test the ability of the material to provide controlled drug delivery. Only an understanding
of the ability of these materials to be combined with other biomaterials and drugs will
allow us to obtain new biomaterials with the necessary properties for use not only in
maxillofacial surgery, but also in healing burns, neurosurgery, cartilage and tendon repair,
and other fields.
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